Close Menu

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Citigroup today lowered revenue estimates for Illumina for the second quarter and for full-year 2011, saying that revenues from a trade-in program for the HiSeq 2000 next-generation sequencing platform would not be a "significant contributor" to total revenues.

Last year, Illumina launched a trade-in program offering customers the opportunity to trade in their Genome Analyzers for the new HiSeq 2000 system.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

According to the Verge, many US states are not including positive results from rapid COVID-19 testing in their case numbers.

Michael Caputo, the top Department of Health and Human Service spokesperson, is taking a leave of absence, CNN says.

CNBC reports that the CDC Director says a SARS-CoV-2 vaccine isn't likely to be generally available until the third quarter of 2021, timing President Donald Trump disputes.

In Nature this week: MassIVE.quant resource houses mass spectrometry-based proteomic data, influence of Viking genetics on European populations, and more.